Lu Liang

Transcriptomic drug repositioning in hepatocellular carcinoma guided by disease signatures and tiered translational evidence

Systemic therapy for hepatocellular carcinoma (HCC) has advanced rapidly. However, durable benefit remains constrained by resistance, tumor heterogeneity, impaired liver function and weak predictive biomarkers. This narrative review examines how HCC disease signatures are constru...